Latest Market News — Page 3
Most recent news items across all covered tickers, sorted chronologically. Wiseek scores each item for market-moving impact; click through for the full AI-ranked analysis.
Up To $60M Licensing Deal, Positive Equity & $10.5M Legal Win Mark Transformative Year For RedHill Biopharma
EXPAREL Real-World Data Reveals Significant Opioid Reduction, Lower Medical Costs for Medicare Hip Patients
GameSquare Experiences Division Achieves Record Q1 2026 Bookings Exceeding $10 Million
Flexsteel Initiates Share Repurchase Program
Clearmind Medicine Eyes FDA Breakthrough Therapy Designation for CMND-100
Greenlane Holdings Regains Nasdaq Bid Price Compliance, Averting Immediate Delisting Threat
Tovecimig Slashes Disease Progression Risk by 56% in Phase 2/3 Biliary Tract Cancer Study
Atlas Lithium Secures Key Partners for Neves Project, Advancing Towards 146K Tonnes Annual Lithium Production
Urban-Gro Completes Strategic Pivot to Sports & Media, Regains Nasdaq Compliance After Financial Turmoil
CorMedix's REZZAYO Phase III Trial Hits Primary Endpoint for Fungal Prophylaxis, Targets $2B Market Expansion
Miluna Acquisition Corp to Merge with AI Software Firm CADV.AI in $408M SPAC Deal
Filament Health Shareholders Approve Acquisition by Red Light Holland, Paving Way for Close
NervGen Pharma Appoints Experienced Biotech CFO Keith Vendola to Lead Financial Strategy
Positive FDA Feedback Advances Alterity's ATH434 Phase 3 Program for MSA
Sagimet Biosciences Prices $175M Stock Offering, Signaling Significant Dilution
GTx-104 FDA CRL Pinpoints Manufacturing Issues, Not Clinical; Phase 3 Data Positive
Alliance Resource Q1 Revenue Drops 4.5% on Coal Weakness; Net Income Hit by Impairment
Lakeland Financial's Q1 EPS hits record $1.04 on 32% net income jump, boosts dividend 4%
Real Brokerage Deal Expected to Boost Earnings, Improve EBITDA Margin
United CEO Kirby Believes Regulators Would Have Approved American Merger
Analysts Project Lower Q2'26 Revenue, EPS for Tyson Foods Amid Cost Pressures
Verizon Posts $3.8 Billion Adjusted Free Cash Flow in Q1
Intellia's Gene-Editing Therapy Achieves 87% Attack Reduction in Phase 3 HAE Trial, BLA Submission Initiated
Psoriasis Drug ORKA-001 Hits 63.5% PASI 100, Supports Potential for Annual Dosing
Ligand to Acquire XOMA Royalty for $739M, Raising 2026 EPS Outlook
Aeluma Taps Veteran Intel Leader Willy Rachmady to Drive Strategic Partnerships, Commercial Scale
Youxin Technology Acquires 18% of TikTok Partner YATOP for $10.8M in Shares, Expanding Digital Commerce
Sionna Therapeutics Completes Enrollment in Key Phase 2a CF Trial, Data Expected This Summer
U.S. Energy Corp. Lands 5-Year Helium Offtake Deal, Securing Long-Term Revenue & De-risking Big Sky Project
SCHMID Group Converts $12M Debt, Proposes €30.75M Equity Swap to Strengthen Balance Sheet